葡萄糖类1受体激动剂和心理健康:系统性审查和元分析
Aureliane C S Pierret1,2,3, Yuya Mizuno2,4,5, Pippa Saunders6
1Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
JAMA psychiatry
|May 14, 2025
概括
类似葡萄糖类1受体激动剂 (GLP1-RAs) 不会增加肥胖或糖尿病患者的精神病风险. GLP1-RA治疗改善了生活质量和饮食行为,有助于整体健康.
科学领域:
- 内分泌学和新陈代谢学
- 精神病学是一个精神病学.
- 临床试验 临床试验
背景情况:
- 肥胖和糖尿病与较差的精神和认知结果以及降低生活质量 (QOL) 有关.
- 葡萄糖类1受体激动剂 (GLP1-RAs) 是已确立的糖尿病和肥胖症的治疗方法.
- GLP1-RAs对精神健康的潜在影响需要进行彻底的调查.
研究的目的:
- 评估GLP1-RA治疗对精神病,认知和QOL结果的影响.
- 进行随机的安慰剂受控试验 (RCT) 的元分析.
主要方法:
- 在 MEDLINE,Embase,PsycINFO 和 CENTRAL 数据库中进行系统搜索.
- 包括超重/肥胖和/或糖尿病的成年人双盲安慰剂对照试验.
- 随机效应对精神病,认知和QOL结果的元分析,具有偏差风险和证据评估的确定性.
主要成果:
- 与安慰剂相比,GLP1-RA治疗在严重或不严重的精神病性不良事件中没有显著差异.
- 在GLP1-RA治疗后,没有观察到抑郁症状严重程度的显著变化.
- GLP1-RA治疗与克制和情绪化的饮食行为以及QOL (心理健康,身体健康,糖尿病相关和体重相关) 的各种方面显著改善有关.
结论:
- 在超重/肥胖和/或糖尿病患者中,GLP1-RA治疗与精神病风险增加或抑郁症状恶化无关.
- GLP1-RAs表现出良好的精神病学安全概况.
- GLP1-RA疗法对身体和情绪健康都有积极的影响,提高了整体生活质量.
相关概念视频
01:24Glucagon-like Receptor Agonists
276
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
276
01:15Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
01:23Antidepressant Drugs: MAOIs and Other Agents
171
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
171
01:06Oral Hypoglycemic Agents: Glinides
114
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
114
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
144
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
144
01:24Mania and Antimanic Drugs: Overview
106
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
106